Known targets — ChEMBL curated mechanism
PIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5
The experimentally established mechanism targets of Buparlisib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA known ✓ | P42336 | 8/20 | 1.00 |
| ▸ | PIK3R1 known ✓ | P27986 | 5/20 | 1.00 |
| ▸ | PIK3CG known ✓ | P48736 | 3/20 | 1.00 |
| ▸ | PIK3CB known ✓ | P42338 | 3/20 | 1.00 |
| ▸ | PIK3R5 known ✓ | Q8WYR1 | 2/20 | 1.00 |
| ▸ | PIK3CD known ✓ | O00329 | 2/20 | 1.00 |
| ▸ | MTOR | P42345 | 11/20 | 1.00 |
| ▸ | PIK3C2B | O00750 | 2/20 | 1.00 |
| ▸ | PRKDC | P78527 | 2/20 | 1.00 |
| ▸ | PIK3C3 | Q8NEB9 | 2/20 | 1.00 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 1.00 |
| ▸ | AKR1C3 | P42330 | 1/20 | 1.00 |
| ▸ | RICTOR | Q6R327 | 1/20 | 0.71 |
| ▸ | RPTOR | Q8N122 | 1/20 | 0.71 |
| ▸ | MAPKAP1 | Q9BPZ7 | 1/20 | 0.71 |
| ▸ | MLST8 | Q9BVC4 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Buparlisib SCHEMBL29387968 | 1.00 | MTOR (1.00) | MTORPIK3CAPIK3R1PIK3CGPIK3CB | |
| Buparlisib SCHEMBL29350945 | 1.00 | MTOR (1.00) | MTORPIK3CAPIK3R1PIK3CGPIK3CB | |
| Buparlisib SCHEMBL29351351 | 1.00 | MTOR (1.00) | MTORPIK3CAPIK3R1PIK3CGPIK3CB | |
| Buparlisib SCHEMBL29493083 | 0.99 | MTOR (0.98) | MTORPIK3CAPIK3R1PIK3CGPIK3CB | |
| Buparlisib SCHEMBL18528952 | 0.99 | MTOR (0.98) | MTORPIK3CAPIK3R1PIK3CGPIK3CB | |
| Buparlisib SCHEMBL896966 | 0.99 | MTOR (0.98) | MTORPIK3CAPIK3R1PIK3CGPIK3CB | |
| Buparlisib SCHEMBL143412 | 0.99 | MTOR (0.98) | MTORPIK3CAPIK3R1PIK3CGPIK3CB | |
| Buparlisib SCHEMBL29412438 | 0.99 | MTOR (0.98) | MTORPIK3CAPIK3R1PIK3CGPIK3CB | |
| Buparlisib SCHEMBL896994 | 0.98 | MTOR (0.96) | MTORPIK3CAPIK3R1PIK3CGPIK3CB | |
| SCHEMBL19460575 | 0.98 | MTOR (0.96) | MTORPIK3CAPIK3R1PIK3CGPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1587 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260053761-A1 | USE OF THYROMIMETICS FOR THE TREATMENT OF CANCER | UNIV OF VERMONT AND STATE AGRICULTURAL COLLEGE (US) | 2026-02-26 | — | — | US | claimed |
| EP-4561704-A2 | USE OF GLYCOGEN METABOLISM INHIBITORS FOR THE TREATMENT OF CANCER | The University Of Vermont (US) | 2025-06-04 | — | — | EP | claimed |
| US-20240252454-A1 | COMPOSITION COMPRISING AN INHIBITOR OF MITOCHONDRIAL TRANSCRIPTION | LEAD DISCOVERY CENTER GMBH (DE) | 2024-08-01 | — | — | US | claimed |
| EP-4333822-A1 | COMPOSITION COMPRISING AN INHIBITOR OF MITOCHONDRIAL TRANSCRIPTION | Lead Discovery Center GmbH (DE) | 2024-03-13 | — | — | EP | claimed |
| US-20240075136-A1 | COMBINATION THERAPIES | NOVARTIS AG (CH) | 2024-03-07 | — | — | US | claimed |
| WO-2024026458-A2 | USE OF GLYCOGEN METABOLISM INHIBITORS FOR THE TREATMENT OF CANCER | THE UNIVERSITY OF VERMONT (US) | 2024-02-01 | — | — | WO | claimed |
| US-20230398115-A1 | MDM2 INHIBITORS AND COMBINATIONS THEREOF | NOVARTIS AG (CH) | 2023-12-14 | — | — | US | claimed |
| EP-4241850-A2 | MDM2 INHIBITORS AND COMBINATIONS THEREOF | Novartis AG (CH) | 2023-09-13 | — | — | EP | claimed |
| US-20230255974-A1 | USE OF THYROMIMETICS FOR THE TREATMENT OF CANCER | UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLEGE | 2023-08-17 | — | — | US | claimed |
| EP-4110344-A2 | USE OF THYROMIMETICS FOR THE TREATMENT OF CANCER | The University Of Vermont (US) | 2023-01-04 | — | — | EP | claimed |
| EP-2259800-A1 | USE OF PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF EGFR DEPENDENT DISEASES OR DISEASES THAT HAVE ACQUIRED RESISTANCE TO AGENTS THAT TARGET EGFR FAMILY MEMBERS | Novartis AG (CH) | 2010-12-15 | — | — | EP | claimed |
| EP-2261223-A1 | Pyrimidine derivatives used as pi-3 kinase inhibitors | Novartis AG (CH) | 2010-12-15 | — | — | EP | claimed |
| WO-2010130779-A2 | COMBINATION OF A PBOSPBOINOSITKLE 3-KSπASE INHIBITOR AND AN ANTIDIABETIC COMPOUND | NOVARTIS AG (CH) | 2010-11-18 | — | — | WO | claimed |
| US-20100272717-A1 | COMBINATIONS OF THERAPEUTIC AGENTS FOR TREATING CANCER | NOVARTIS AG (CH) | 2010-10-28 | — | — | US | claimed |
| EP-2231147-A2 | COMBINATIONS OF THERAPEUTIC AGENTS FOR TREATING CANCER | Novartis AG (CH) | 2010-09-29 | — | — | EP | claimed |
| EP-1984350-B1 | PYRIMIDINE DERIVATIVES USED AS PI-3 KINASE INHIBITORS | NOVARTIS AG (CH) | 2010-08-18 | — | — | EP | claimed |
| WO-2010049481-A1 | COMBINATION OF A PHOSPHATIDYLINOSITOL-3-KINASE (PI3K) INHIBITOR AND A MTOR INHIBITOR | NOVARTIS AG (CH) | 2010-05-06 | — | — | WO | claimed |
| WO-2009118324-A1 | 5IMIDAZOQUINOLINES AND PYRIMIDINE DERIVATIVES AS POTENT MODULATORS OF VEGF-DRIVEN ANGIOGENIC PROCESSES | NOVARTIS AG (CH) | 2009-10-01 | — | — | WO | claimed |
| WO-2009109605-A1 | USE OF PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF EGFR DEPENDENT DISEASES OR DISEASES THAT HAVE ACQUIRED RESISTANCE TO AGENTS THAT TARGET EGFR FAMILY MEMBERS | NOVARTIS AG (CH) | 2009-09-11 | — | — | WO | claimed |
| WO-2009076170-A2 | COMBINATIONS OF THERAPEUTIC AGENTS FOR TREATING CANCER | NOVARTIS AG (CH) | 2009-06-18 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100272717-A1 | COMBINATIONS OF THERAPEUTIC AGENTS FOR TREATING CANCER | ANXA5, BAX, ANXA6 | PIK3CA 108/4885PIK3R1 593/4885PIK3CG 503/4885 |
| US-20240252454-A1 | COMPOSITION COMPRISING AN INHIBITOR OF MITOCHONDRIAL TRANSCRIPTION | TFAM, POLRMT, TUFM | PIK3CA 2374/4885PIK3R1 1207/4885PIK3CG 1888/4885 |
| US-20230398115-A1 | MDM2 INHIBITORS AND COMBINATIONS THEREOF | TP53, MDM2, BCL2 | PIK3CA 86/4885PIK3R1 94/4885PIK3CG 272/4885 |
| US-20260053761-A1 | USE OF THYROMIMETICS FOR THE TREATMENT OF CANCER | THRA, THRB, TRHR | PIK3CA 2438/4885PIK3R1 3074/4885PIK3CG 3569/4885 |
| US-20240075136-A1 | COMBINATION THERAPIES | BRCA1, TP53, VHL | PIK3CA 884/4885PIK3R1 3197/4885PIK3CG 2762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.